RegentAtlantic Capital’s GSK GSK Stock Holding History

RegentAtlantic Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,986	Closed	-$217K	–	689
2022 Q1	$217K	Buy	+3,986	New	+$217K	0.01%	643
2021 Q4	–	Sell	-4,227	Closed	-$202K	–	693
2021 Q3	$202K	Buy	+4,227	New	+$212K	0.01%	636
2020 Q4	–	Sell	-13,377	Closed	-$629K	–	512
2020 Q3	$629K	Buy	13,377 +9,400	+236%	+$471K	0.03%	292
2020 Q2	$203K	Buy	+3,977	New	+$204K	0.01%	453
2017 Q4	–	Sell	-5,167	Closed	-$262K	–	424
2017 Q3	$262K	Sell	5,167 -7	-0.1%	-$355	0.02%	353
2017 Q2	$279K	Buy	5,174 +80	+2%	+$4.26K	0.03%	341
2017 Q1	$268K	Buy	+5,094	New	+$258K	0.02%	348
2016 Q4	–	Sell	-4,110	Closed	-$222K	–	390
2016 Q3	$222K	Sell	4,110 -858	-17%	-$47K	0.02%	358
2016 Q2	$269K	Sell	4,968 -403	-8%	-$21.2K	0.03%	336
2016 Q1	$272K	Buy	5,371 +691	+15%	+$34.4K	0.03%	326
2015 Q4	$236K	Buy	+4,680	New	+$239K	0.03%	339
2015 Q1	–	Sell	-2,478	Closed	-$132K	–	569
2014 Q4	$132K	Buy	+2,478	New	+$139K	0.01%	419

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

RegentAtlantic Capital's GSK Position: Q2 2022 in Review

RegentAtlantic Capital sold out of GSK (GSK) in Q2 2022, closing a stake of 3,986 shares — an estimated $217K sold.

RegentAtlantic Capital first reported a position in GSK in Q4 2014 and held it in 12 quarters. The position peaked at $629K in Q3 2020. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

RegentAtlantic Capital reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
RegentAtlantic Capital sold 3,986 GSK shares in Q2 2022, an estimated $217K.
RegentAtlantic Capital first reported a position in GSK in Q4 2014 and held it in 12 quarters.
RegentAtlantic Capital's GSK position peaked at $629K in Q3 2020.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on RegentAtlantic Capital's 13F filing for Q2 2022, filed 15 Aug 2022.